SCHEMBL10245280

SCHEMBL10245280

CCNC(=O)CNC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.41
FAAH O00519 1/20 0.40
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP3 P08254 1/20 0.34
MMP9 P14780 1/20 0.34
MMP8 P22894 1/20 0.34
DPP4 P27487 3/20 0.34
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.31
RECQL P46063 1/20 0.31
MEN1 O00255 1/20 0.31
DPP8 Q6V1X1 1/20 0.31
DPP9 Q86TI2 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21891278 0.82 MCL1 (0.45) MCL1FAAHMMP1MMP2MMP3
SCHEMBL18272883 0.79 MEN1 (0.34) DPP4KMT2AALDH1A1RECQLMEN1
SCHEMBL14805819 0.79 EGLN1 (0.40) FAAHDPP4KMT2AALDH1A1KDM4E
SCHEMBL20261178 0.79 DPP4 (0.37) DPP4RECQLDPP8DPP9
SCHEMBL24765242 0.77 EGLN1 (0.39) FAAHDPP4KMT2AALDH1A1KDM4E
SCHEMBL8056854 0.77 RECQL (0.33) DPP4RECQL
SCHEMBL24764834 0.77 HDAC4 (0.33) MCL1DPP4ALDH1A1RECQL
SCHEMBL25760253 0.77 MAPT (0.35) DPP4ALDH1A1GAARECQLDPP8
SCHEMBL24766205 0.77 EGLN1 (0.39) FAAHDPP4KMT2AALDH1A1KDM4E
SCHEMBL25748793 0.77 MAPT (0.35) DPP4ALDH1A1GAARECQLDPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 US disclosed
CN-112341446-B Immunomodulator 成都先导药物开发股份有限公司 2022-06-17 CN disclosed
CN-112341440-B Immunomodulator 成都先导药物开发股份有限公司 2022-05-31 CN disclosed
EP-3889145-A1 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS Merck Patent GmbH (DE) 2021-10-06 EP disclosed
EP-3889146-A1 POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS Merck Patent GmbH (DE) 2021-10-06 EP disclosed
WO-2017106607-A1 POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS MERCK PATENT GMBH (DE) 2017-06-22 WO disclosed
US-20170174653-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-06-22 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 MCL1 471/4885FAAH 1883/4885MMP1 4705/4885
US-20170174653-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 MCL1 698/4885FAAH 1409/4885MMP1 4719/4885
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 MCL1 2310/4885FAAH 4386/4885MMP1 266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.